Exchange: NASDAQ·Updated 07:45 PM EDT
News
all
press releases
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of +400.00% and +11.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +200.00% and +4.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here's Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors
Here's Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors...
Yahoo! Finance: News
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday
US stock futures mixed, Cisco and MaxCyte report positive earnings, Alibaba and Vishay to release results.read more...
Benzinga
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of +57.90% and +31.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday
MaxCyte (NASDAQ:MXCT) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...
MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Receives Consensus Rating of "Hold" from Brokerages
MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) has earned a consensus recommendation of "Hold" from the five brokerages that are covering the stock, MarketBeat reports. One equities research analyst...
MarketBeat

Advertisement|Remove ads.